MethylGene Inc. Report issue

For profit Phase 1 Phase 2
Founded: Montreal Canada (1997)
Status: Acquired by Mirati Therapeutics Inc. (2013) → now Bristol-Myers Squibb (2023)

Organization Overview

First Clinical Trial
2004
NCT00323934
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Candidiasis (Phase 2)

Candidiasis, Vulvovaginal (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Hodgkin Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Preleukemia (Phase 2)

Prostatic Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 17
  • # of Trial APIs: 8